Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthroughs against otherwise undruggable disease-causing targets, has announced the first target for the development of a small molecule inhibitor is advancing into the lead generation phase under the company’s global partnership with AbbVie.
 
The global partnership was established in December 2020 to discover, develop, and commercialize a pipeline of innovative small molecule therapeutics against certain high-interest, difficult-to-drug protein targets.
 
“AbbVie’s partnership with Frontier continues to advance our ongoing efforts and strategic focus on difficult-to-drug protein targets,” said Jonathon Sedgwick, Ph.D., vice president and global head, Discovery Research, AbbVie. “We are encouraged by the potential of this technology to validate and drug previously inaccessible biology, with the ultimate aim of developing new medicines to treat patients with debilitating or life-threatening disease.”
 
Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, added, “The rapid advancement of our first collaboration program against a very important but historically intractable target is a testament to the uniqueness of our platform technologies, bringing together chemoproteomics, covalent chemistry, and machine learning, as well as the expertise of our scientific team. We are pleased to have achieved this first milestone, and we look forward to continued progress with this program and others through the productive collaboration with AbbVie.”